| Autor: |
Nicole S, Fraser, Christine M, Knauth, Elizna M, Schoeman, Assia, Moussa, Andrew C, Perkins, Terry, Walsh, Glenda M, Millard, Melinda M, Dean, Catherine A, Hyland, Robert L, Flower |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
Transfusion. 58(10) |
| ISSN: |
1537-2995 |
| Popis: |
KLF1 is an essential transcriptional activator that drives erythropoiesis. KLF1 variants can result in the Inhibitor of Lutheran, or In(Lu), phenotype where red blood cells (RBCs) have reduced BCAM (LU) and CD44 (IN). Other RBC surface molecules also have changed expression; however, there is controversy in the literature regarding which are truly impacted. We aimed to investigate KLF1 variants in the Australian population.In(Lu) samples were sourced through screening and through the RBC reference laboratory. Blood donor samples (8036) were screened to identify weakened/absent LuFour of 8036 donors were identified to be In(Lu), and two previously identified In(Lu) samples were provided from the RBC reference laboratory. Five different KLF1 variants were identified; two were novel: c.954GC/p.Trp318Cys and c.421CT/p.Arg141*. BCAM and CD44 were reduced in all samples, consistent with previous reports. As a group, In(Lu) RBCs had reduced CD35 (KN), ICAM4 (LW), and CD147 (OK), and demonstrated increased binding of lectins ECA and SNAI. One In(Lu) sample had elevated HbF and another elevated HbA2.Different KLF1 variants may potentially produce variable phenotypes. A framework for investigating KLF1 variants and their phenotypic impact has been provided. In the future, given available international databases, further testing algorithms (as advocated here) will allow for correlation of phenotype with genotype and therefore accurately document this variability between KLF1 variants. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text